Matt Karpen

Matt Karpen joined Lung Therapeutics in 2018 as Director of CMC. Mr. Karpen brings approximately 20 years of biopharmaceutical experience to Lung Therapeutics, including various leadership positions in process development, process engineering, process scale-up, and technology transfer, cGMP operations support, and clinical and commercial manufacturing. Most recently, Mr. Karpen was a senior leader in the process validation strategy group within technical operations at Shire. There he developed and implemented innovative process qualification, characterization, and controls strategies in support of several orphan drug and breakthrough therapies submissions. Prior to this, Mr. Karpen held various leadership roles at Amgen where he developed and implemented industry-leading strategies for process scale-up and tech transfer, product changeover, and new product introduction, and supported the "manufacturing of the future" platform. At Amgen, Mr. Karpen was part of several successful commercial regulatory submissions. Mr. Karpen began his biopharmaceutical career at Pfizer within the process development organization and performed pilot plant operations, tech transfer, and supported the start-up of a cGMP clinical manufacturing facility. Mr. Karpen received his Bachelor of Science in Engineering from the University of Dayton. He is published in BioPharm International and is a co-author of PDA Technical Report 56.